Original Article

You have full text access to this OnlineOpen article

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats†

  1. Magali Gary-Bobo,
  2. Ghizlane Elachouri,
  3. Jean François Gallas,
  4. Philip Janiak,
  5. Pietro Marini,
  6. Christine Ravinet-Trillou,
  7. Michèle Chabbert,
  8. Noël Cruccioli,
  9. Christian Pfersdorff,
  10. Claude Roque,
  11. Michèle Arnone,
  12. Tiziano Croci,
  13. Philippe Soubrié,
  14. Florence Oury-Donat,
  15. Jean Pierre Maffrand,
  16. Bernard Scatton,
  17. Frederic Lacheretz,
  18. Gérard Le Fur,
  19. Jean Marc Herbert,
  20. Mohammed Bensaid‡,*

Article first published online: 24 MAY 2007

DOI: 10.1002/hep.21641

Issue

Hepatology

Hepatology

Volume 46, Issue 1, pages 122–129, July 2007

Additional Information

How to Cite

Gary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., Arnone, M., Croci, T., Soubrié, P., Oury-Donat, F., Maffrand, J. P., Scatton, B., Lacheretz, F., Le Fur, G., Herbert, J. M. and Bensaid, M. (2007), Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology, 46: 122–129. doi: 10.1002/hep.21641

Author Information

  1. Sanofi-Aventis Recherche & Développement, Discovery Research CNS Department, Montpellier, France

  1. ‡

    fax: (33-4) 9977-69-12

*Sanofi-Aventis Recherche, CNS Research Department, 371, rue du Professeur J. Blayac, F-34184 Montpellier Cédex 04, France

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 27 JUN 2007
  2. Article first published online: 24 MAY 2007
  3. Manuscript Accepted: 5 JAN 2007
  4. Manuscript Received: 30 AUG 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (431K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sawsan A Zaitone, Soha Essawy, Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats, Clinical and Experimental Pharmacology and Physiology, 2012, 39, 6
    Direct Link:
  2. 2
    Tony Jourdan, Laurent Demizieux, Joseph Gresti, Louiza Djaouti, Lila Gaba, Bruno Vergès, Pascal Degrace, Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants, Hepatology, 2012, 55, 3
    Direct Link:
  3. 3
    Mónica Alonso, Antonia Serrano, Margarita Vida, Ana Crespillo, Laura Hernandez-Folgado, Nadine Jagerovic, Pilar Goya, Carmen Reyes-Cabello, Vidal Perez-Valero, Juan Decara, Manuel Macías-González, Francisco Javier Bermúdez-Silva, Juan Suárez, Fernando Rodríguez de Fonseca, Francisco Javier Pavón, Anti-obesity efficacy of LH-21, a cannabinoid CB1 receptor antagonist with poor brain penetration, in diet-induced obese rats, British Journal of Pharmacology, 2012, 165, 7
    Direct Link:
  4. 4
    Florence Pietu, Olivier Guillaud, Thomas Walter, Mélanie Vallin, Valérie Hervieu, Jean-Yves Scoazec, Jérôme Dumortier, Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results, Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 2, 146

    CrossRef

  5. 5
    James Neuberger, Zakim and Boyer's Hepatology, 2012,

    CrossRef

  6. 6
    Laura H. Jacobson, S. Renee Commerford, Sarah P. Gerber, Yu Alice Chen, Beatriz Dardik, Frederique Chaperon, Chad Schwartzkopf, Van Nguyen-Tran, Thomas Hollenbeck, Peter McNamara, Xiaohui He, Hong Liu, H. Martin Seidel, Anne-Liese Jaton, Jesper Gromada, Sandra Teixeira, Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity, Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384, 6, 565

    CrossRef

  7. 7
    K S Bell-Anderson, L Aouad, H Williams, F R Sanz, J Phuyal, C Z Larter, G C Farrell, I D Caterson, Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice, International Journal of Obesity, 2011, 35, 12, 1539

    CrossRef

  8. 8
    J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome, Current therapeutic strategies in non-alcoholic fatty liver disease, Diabetes, Obesity and Metabolism, 2011, 13, 8
    Direct Link:
  9. 9
    Ravi Murumalla, Karima Bencharif, Lydie Gence, Amritendu Bhattacharya, Frank Tallet, Marie-Paule Gonthier, Stefania Petrosino, Vincenzo di Marzo, Maya Cesari, Laurence Hoareau, Régis Roche, Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation, Journal of Inflammation, 2011, 8, 1, 33

    CrossRef

  10. 10
    M. Flamment, Effets du blocage des récepteurs CB1 par le rimonabant sur la fonction mitochondriale hépatique, Obésité, 2011, 6, 3, 184

    CrossRef

  11. 11
    Wei-na Cong, Rong-ya Tao, Jin-ying Tian, Jiong Zhao, Qian Liu, Fei Ye, EGb761, an extract of Ginkgo biloba leaves, reduces insulin resistance in a high-fat-fed mouse model, Acta Pharmaceutica Sinica B, 2011, 1, 1, 14

    CrossRef

  12. 12
    Joseph Tam, Jie Liu, Bani Mukhopadhyay, Resat Cinar, Grzegorz Godlewski, George Kunos, Endocannabinoids in liver disease, Hepatology, 2011, 53, 1
    Direct Link:
  13. 13
    Partha Mukhopadhyay, Bėla Horváth, Mohanraj Rajesh, Shingo Matsumoto, Keita Saito, Sándor Bátkai, Vivek Patel, Galin Tanchian, Rachel Y. Gao, Benjamin F. Cravatt, György Haskó, Pál Pacher, Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury, Free Radical Biology and Medicine, 2011, 50, 1, 179

    CrossRef

  14. 14
    Angelina Mouralidarane, Jude A. Oben, Junpei Soeda, Pathophysiology and clinical management of non-alcoholic fatty liver disease, Medicine, 2011, 39, 10, 592

    CrossRef

  15. 15
    Cristoforo Silvestri, Alessia Ligresti, Vincenzo Marzo, Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle, Reviews in Endocrine and Metabolic Disorders, 2011, 12, 3, 153

    CrossRef

  16. 16
    Changyu Pan, Hyung Joon Yoo, Low-Tone Ho, Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia, Journal of Obesity, 2011, 2011, 1

    CrossRef

  17. 17
    Masashi Inafuku, Koji Nagao, Saori Nomura, Bungo Shirouchi, Nao Inoue, Naoki Nagamori, Hideyuki Nakayama, Takayoshi Toda, Teruyoshi Yanagita, Protective effects of fractional extracts from Panellus serotinus on non-alcoholic fatty liver disease in obese, diabetic db/db mice, British Journal of Nutrition, 2011, 107, 05, 639

    CrossRef

  18. 18
    Jogeswar Mohapatra, Manoranjan Sharma, Aviseka Acharya, Gaurav Pandya, Abhijit Chatterjee, R Balaraman, Mukul R Jain, Retinol-binding protein 4 : a possible role in cardiovascular complications, British Journal of Pharmacology, 2011, 164, 8
    Direct Link:
  19. You have free access to this content19
    A Mallat, F Teixeira-Clerc, V Deveaux, S Manin, S Lotersztajn, The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings, British Journal of Pharmacology, 2011, 163, 7
    Direct Link:
  20. 20
    Patrice D. Cani, Nathalie M. Delzenne, The gut microbiome as therapeutic target, Pharmacology & Therapeutics, 2011, 130, 2, 202

    CrossRef

  21. 21
    Giulio Marchesini, Simona Moscatiello, Federica Agostini, Nicola Villanova, Davide Festi, Treatment of non-alcoholic fatty liver disease with focus on emerging drugs, Expert Opinion on Emerging Drugs, 2011, 16, 1, 121

    CrossRef

  22. 22
    Paolo Lazzari, Angela Sanna, Andrea Mastinu, Simona Cabasino, Ilaria Manca, Luca Pani, Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice, Behavioural Brain Research, 2011, 217, 2, 432

    CrossRef

  23. 23
    Mohanraj Rajesh, Partha Mukhopadhyay, György Haskó, Lucas Liaudet, Ken Mackie, Pál Pacher, Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells, British Journal of Pharmacology, 2010, 160, 3
    Direct Link:
  24. 24
    Partha Mukhopadhyay, Hao Pan, Mohanraj Rajesh, Sándor Bátkai, Vivek Patel, Judith Harvey-White, Bani Mukhopadhyay, György Haskó, Bin Gao, Ken Mackie, Pál Pacher, CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model, British Journal of Pharmacology, 2010, 160, 3
    Direct Link:
  25. 25
    Amedeo Lonardo, Stephen H Caldwell, Paola Loria, Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment, Expert Review of Endocrinology & Metabolism, 2010, 5, 3, 403

    CrossRef

  26. 26
    Ying-Ying Yang, Han-Chieh Lin, Cross-regulation of cannabinoid CB1 and CB2 receptors governs hepatic steatosis, Liver International, 2010, 30, 10
    Direct Link:
  27. 27
    Vincenzo Di Marzo, Mikko Griinari, Gianfranca Carta, Elisabetta Murru, Alessia Ligresti, Lina Cordeddu, Elena Giordano, Tiziana Bisogno, Maria Collu, Barbara Batetta, Sabrina Uda, Kjetil Berge, Sebastiano Banni, Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats, International Dairy Journal, 2010, 20, 4, 231

    CrossRef

  28. 28
    Qun Wang, Xiaoyuan D. Perrard, Jerry L. Perrard, Amir Mansoori, C. Wayne Smith, Christie M. Ballantyne, Huaizhu Wu, Effect of the Cannabinoid Receptor-1 Antagonist Rimonabant on Inflammation in Mice With Diet-Induced Obesity, Obesity, 2010, 19, 3, 505

    CrossRef

  29. 29
    Signe Mølhøj, Harald S. Hansen, Martina Schweiger, Robert Zimmermann, Thue Johansen, Kjell Malmlöf, Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats, European Journal of Pharmacology, 2010, 646, 1-3, 38

    CrossRef

  30. 30
    Ariane Mallat, Sophie Lotersztajn, Endocannabinoids in the pathophysiology of obesity – The liver, Drug Discovery Today: Disease Mechanisms, 2010, 7, 3-4, e185

    CrossRef

  31. 31
    Marcin Krawczyk, Leonilde Bonfrate, Piero Portincasa, Nonalcoholic fatty liver disease, Best Practice & Research Clinical Gastroenterology, 2010, 24, 5, 695

    CrossRef

  32. 32
    Jeffrey R. Lewis, Smruti R. Mohanty, Nonalcoholic Fatty Liver Disease: A Review and Update, Digestive Diseases and Sciences, 2010, 55, 3, 560

    CrossRef

  33. 33
    Joseph Tam, V. Kiran Vemuri, Jie Liu, Sándor Bátkai, Bani Mukhopadhyay, Grzegorz Godlewski, Douglas Osei-Hyiaman, Shinobu Ohnuma, Suresh V. Ambudkar, James Pickel, Alexandros Makriyannis, George Kunos, Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity, Journal of Clinical Investigation, 2010, 120, 8, 2953

    CrossRef

  34. 34
    Giovanni Targher, Alessandro Bellis, Paolo Fornengo, Francesca Ciaravella, Isabella Pichiri, Paolo Cavallo Perin, Bruno Trimarco, Giulio Marchesini, Prevention and treatment of nonalcoholic fatty liver disease, Digestive and Liver Disease, 2010, 42, 5, 331

    CrossRef

  35. 35
    Laurent Hortala, Murielle Rinaldi-Carmona, Christian Congy, Laurent Boulu, Freddy Sadoun, Gérard Fabre, Olivier Finance, Francis Barth, Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 15, 4573

    CrossRef

  36. 36
    Alexandra Miranville, Andreas W. Herling, Gabriele Biemer-Daub, Marc D. Voss, Reversal of Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages, Obesity, 2010, 18, 12, 2247

    CrossRef

  37. 37
    Vishnudutt Purohit, Rao Rapaka, David Shurtleff, Role of Cannabinoids in the Development of Fatty Liver (Steatosis), The AAPS Journal, 2010, 12, 2, 233

    CrossRef

  38. 38
    Jukka Westerbacka, Anna Kotronen, Barbara A. Fielding, John Wahren, Leanne Hodson, Julia Perttilä, Tuulikki Seppänen–Laakso, Tapani Suortti, Johanna Arola, Rolf Hultcrantz, Sandra Castillo, Vesa M. Olkkonen, Keith N. Frayn, Matej Orešič, Hannele Yki–Järvinen, Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease, Gastroenterology, 2010, 139, 6, 1961

    CrossRef

  39. 39
    Giulio G Muccioli, Damien Naslain, Fredrik Bäckhed, Christopher S Reigstad, Didier M Lambert, Nathalie M Delzenne, Patrice D Cani, The endocannabinoid system links gut microbiota to adipogenesis, Molecular Systems Biology, 2010, 6,

    CrossRef

  40. 40
    Henrik H. Hansen, Gitte Hansen, Mads Tang-Christensen, Philip J. Larsen, Anne Marie D. Axel, Anne Raben, Jens D. Mikkelsen, The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant, European Journal of Pharmacology, 2010, 636, 1-3, 88

    CrossRef

  41. 41
    Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Eleni Tsiaousi, The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease, Diabetes, Obesity and Metabolism, 2010, 12, 5
    Direct Link:
  42. 42
    Tirumala Rajesh, Karunanidhi Santhana Lakshmi, Shrinivas Sharma, Pulukurthy Dileep Reddy, Sivasubramanian Lakshmi, Use of a validated stability-indicating HPTLC method to study the degradation of rimonabant, JPC - Journal of Planar Chromatography - Modern TLC, 2010, 23, 2, 148

    CrossRef

  43. 43
    Jacqueline G. O’Leary, Gary L. Davis, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  44. 44
    Youngmin Lee, Scott L. Friedman, Development, Differentiation and Disease of the Para-Alimentary Tract, 2010,

    CrossRef

  45. 45
    F. Akbas, C. Gasteyger, A. Sjödin, A. Astrup, T. M. Larsen, A critical review of the cannabinoid receptor as a drug target for obesity management, Obesity Reviews, 2009, 10, 1
    Direct Link:
  46. 46
    Zhongsheng Peng, Pier Andrea Borea, Tuere Wilder, Herman Yee, Luis Chiriboga, Michael R. Blackburn, Gianfranco Azzena, Giuseppe Resta, Bruce N. Cronstein, Adenosine signaling contributes to ethanol-induced fatty liver in mice, Journal of Clinical Investigation, 2009, 119, 3, 582

    CrossRef

  47. 47
    Marie Maynadier, Ilaria Basile, Magali Gary-Bobo, Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant, Drug Discovery Today, 2009, 14, 3-4, 192

    CrossRef

  48. 48
    Prakash Nagarkatti, Rupal Pandey, Sadiye Amcaoglu Rieder, Venkatesh L Hegde, Mitzi Nagarkatti, Cannabinoids as novel anti-inflammatory drugs, Future Medicinal Chemistry, 2009, 1, 7, 1333

    CrossRef

  49. 49
    C. Hezode, A. Mallat, Comorbidité et hépatotoxicité du tabac et des substances récréatives, Gastroentérologie Clinique et Biologique, 2009, 33, 12, 1131

    CrossRef

  50. 50
    Mohamed H. Ahmed, Christopher D. Byrne, Current treatment of non-alcoholic fatty liver disease, Diabetes, Obesity and Metabolism, 2009, 11, 3
    Direct Link:
  51. 51
    T. Pusl, C. Rust, K.G. Parhofer, Diabetes und Fettleber, Der Diabetologe, 2009, 5, 8, 653

    CrossRef

  52. 52
    Daniela Cota, Darleen A. Sandoval, Massimiliano Olivieri, Elena Prodi, David A. D'Alessio, Stephen C. Woods, Randy J. Seeley, Silvana Obici, Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism, Obesity, 2009, 17, 8, 1641

    CrossRef

  53. 53
    S. Petta, C. Muratore, A. Craxì, Non-alcoholic fatty liver disease pathogenesis: The present and the future, Digestive and Liver Disease, 2009, 41, 9, 615

    CrossRef

  54. 54
    Raj Vuppalanchi, Naga Chalasani, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management, Hepatology, 2009, 49, 1
    Direct Link:
  55. 55
    Nila Rafiq, Zobair M. Younossi, Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management, Clinics in Liver Disease, 2009, 13, 2, 249

    CrossRef

  56. 56
    Fabien Forcheron, Pauline Abdallah, Alexandra Basset, Peggy del Carmine, Ghina Haffar, Michel Beylot, Nonalcoholic Hepatic Steatosis in Zucker Diabetic Rats: Spontaneous Evolution and Effects of Metformin and Fenofibrate, Obesity, 2009,

    CrossRef

  57. 57
    M. Contestin, J.-L. Wemeau, Obésité, stéatose et insulinorésistance. D’après le Symposium III, Congrès de l’ALFEDIAM, Bruxelles, 27 mars 2008, Annales d'Endocrinologie, 2009, 70, 4, 262

    CrossRef

  58. You have free access to this content58
    Angelo A Izzo, Fabiana Piscitelli, Raffaele Capasso, Gabriella Aviello, Barbara Romano, Francesca Borrelli, Stefania Petrosino, Vincenzo Di Marzo, Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding, British Journal of Pharmacology, 2009, 158, 2
    Direct Link:
  59. 59
    Ka-Kit Li, James Neuberger, Recurrent nonviral liver disease following liver transplantation, Expert Review of Gastroenterology & Hepatology, 2009, 3, 3, 257

    CrossRef

  60. 60
    Fabrizio Montecucco, Isabel Matias, Sébastien Lenglet, Stefania Petrosino, Fabienne Burger, Graziano Pelli, Vincent Braunersreuther, François Mach, Sabine Steffens, Vincenzo Di Marzo, Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis, Atherosclerosis, 2009, 205, 2, 433

    CrossRef

  61. 61
    Midori Kojima, Naoto Kato, Daisuke Hirano, Takashi Ochi, Aisuke Nii, Katsuhiro Shinjo, Hiroyuki Eda, Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A, Hepatology Research, 2009, 39, 4
    Direct Link:
  62. 62
    George Kunos, Douglas Osei-Hyiaman, Sándor Bátkai, Keith A. Sharkey, Alexandros Makriyannis, Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?, Trends in Pharmacological Sciences, 2009, 30, 1, 1

    CrossRef

  63. 63
    Henry N. Ginsberg, Stephen C. Woods, The Endocannabinoid System: Potential for Reducing Cardiometabolic Risk, Obesity, 2009, 17, 10, 1821

    CrossRef

  64. 64
    Paolo Caraceni, Marco Domenicali, Ferdinando Giannone, Mauro Bernardi, The role of the endocannabinoid system in liver diseases, Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 1, 65

    CrossRef

  65. 65
    Paul Cavuoto, Gary A. Wittert, The role of the endocannabinoid system in the regulation of energy expenditure, Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 1, 79

    CrossRef

  66. 66
    F. Montecucco, F. Mach, Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome, Diabetes, Obesity and Metabolism, 2009, 11, 5
    Direct Link:
  67. 67
    Wolfgang Lieb, Alisa K. Manning, Jose C. Florez, Josée Dupuis, L. Adrienne Cupples, Jarred B. McAteer, Ramachandran S. Vasan, Udo Hoffmann, Christopher J. O'Donnell, James B. Meigs, Caroline S. Fox, Variants in the CNR1 and the FAAH Genes and Adiposity Traits in the Community, Obesity, 2009, 17, 4, 755

    CrossRef

  68. 68
    A. Mallat, S. Lotersztajn, Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis, Diabetes & Metabolism, 2008, 34, 6, 680

    CrossRef

  69. 69
    K. Eckardt, H. Sell, A. Taube, M. Koenen, B. Platzbecker, A. Cramer, A. Horrighs, M. Lehtonen, N. Tennagels, J. Eckel, Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle, Diabetologia, 2008, 52, 4, 664

    CrossRef

  70. You have free access to this content70
    Partha Mukhopadhyay, Rajesh Mohanraj, Sándor Bátkai, Pál Pacher, CB1 Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?, Congestive Heart Failure, 2008, 14, 6
    Direct Link:
  71. 71
    Vincenzo Di Marzo, CB1 receptor antagonism: biological basis for metabolic effects, Drug Discovery Today, 2008, 13, 23-24, 1026

    CrossRef

  72. 72
    Tim Fulmer, CB1's peripheral vision, Science-Business eXchange, 2008, 1, 31, 1

    CrossRef

  73. 73
    Christophe Hézode, Elie Serge Zafrani, Françoise Roudot–Thoraval, Charlotte Costentin, Ali Hessami, Magali Bouvier–Alias, Fatiha Medkour, Jean–Michel Pawlostky, Sophie Lotersztajn, Ariane Mallat, Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C, Gastroenterology, 2008, 134, 2, 432

    CrossRef

  74. 74
    Stanislas Grassin Delyle, Emuri Abe, Philippe Devillier, Jean Claude Alvarez, Determination of rimonabant in human plasma and hair by liquid chromatography–mass spectrometry, Journal of Chromatography B, 2008, 872, 1-2, 115

    CrossRef

  75. 75
    Dawn M. Torres, Stephen A. Harrison, Diagnosis and Therapy of Nonalcoholic Steatohepatitis, Gastroenterology, 2008, 134, 6, 1682

    CrossRef

  76. You have free access to this content76
    S. Engeli, Dysregulation of the Endocannabinoid System in Obesity, Journal of Neuroendocrinology, 2008, 20,
    Direct Link:
  77. 77
    David Jesudason, Gary Wittert, Endocannabinoid system in food intake and metabolic regulation, Current Opinion in Lipidology, 2008, 19, 4, 344

    CrossRef

  78. 78
    George Kunos, Bin Gao, Endocannabinoids, CB1 Receptors, and Liver Disease: Hitting More Than One Bird With the Same Stone, Gastroenterology, 2008, 134, 2, 622

    CrossRef

  79. 79
    Timothy P. Carr, Elliot D. Jesch, Andrew W. Brown, Endocannabinoids, metabolic regulation, and the role of diet, Nutrition Research, 2008, 28, 10, 641

    CrossRef

  80. 80
    Ariane Mallat, Christophe Hezode, Sophie Lotersztajn, Environmental factors as disease accelerators during chronic hepatitis C, Journal of Hepatology, 2008, 48, 4, 657

    CrossRef

  81. 81
    S. Strahl, K.P. Maier, Gibt es Therapieansätze für die nicht-alkoholische Fettleber und ihre Komplikationen?, Der Internist, 2008, 49, 12, 1421

    CrossRef

  82. 82
    Douglas Osei-Hyiaman, Jie Liu, Liang Zhou, Grzegorz Godlewski, Judith Harvey-White, Won-il Jeong, Sándor Bátkai, Giovanni Marsicano, Beat Lutz, Christoph Buettner, George Kunos, Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, Journal of Clinical Investigation, 2008, 118, 9, 3160

    CrossRef

  83. 83
    Helena Cortez-Pinto, Mariana Machado, Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease, Expert Review of Gastroenterology & Hepatology, 2008, 2, 2, 217

    CrossRef

  84. 84
    André J Scheen, Nicolas Paquot, Inhibitors of cannabinoid receptors and glucose metabolism, Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 4, 505

    CrossRef

  85. 85
    Nimantha Mark Wilfred de Alwis, Christopher Paul Day, Non-alcoholic fatty liver disease: The mist gradually clears, Journal of Hepatology, 2008, 48, S104

    CrossRef

  86. 86
    Won-il Jeong, Douglas Osei-Hyiaman, Ogyi Park, Jie Liu, Sándor Bátkai, Partha Mukhopadhyay, Norio Horiguchi, Judith Harvey-White, Giovanni Marsicano, Beat Lutz, Bin Gao, George Kunos, Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver, Cell Metabolism, 2008, 7, 3, 227

    CrossRef

  87. 87
    Laurie D. DeLeve, Xiangdong Wang, Gary C. Kanel, Roscoe D. Atkinson, Robert S. McCuskey, Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Nonalcoholic Steatohepatitis, The American Journal of Pathology, 2008, 173, 4, 993

    CrossRef

  88. 88
    V Di Marzo, A Szallasi, Rimonabant in rats with a metabolic syndrome: good news after the depression, British Journal of Pharmacology, 2008, 154, 5
    Direct Link:
  89. 89
    Jun Wang, Natsuo Ueda, Role of the endocannabinoid system in metabolic control, Current Opinion in Nephrology and Hypertension, 2008, 17, 1, 1

    CrossRef

  90. 90
    Vincenzo Di Marzo, Targeting the endocannabinoid system: to enhance or reduce?, Nature Reviews Drug Discovery, 2008, 7, 5, 438

    CrossRef

  91. 91
    Roja Motaghedi, Timothy E. McGraw, The CB1 Endocannabinoid System Modulates Adipocyte Insulin Sensitivity, Obesity, 2008, 16, 8, 1727

    CrossRef

  92. You have free access to this content92
    P. Caraceni, M. Domenicali, M. Bernardi, The Endocannabinoid System and Liver Diseases, Journal of Neuroendocrinology, 2008, 20,
    Direct Link:
  93. 93
    V. Marzo, The endocannabinoid system in obesity and type 2 diabetes, Diabetologia, 2008, 51, 8, 1356

    CrossRef

  94. 94
    Stefan Engeli, The endocannabinoid system, Obesity, and insulin resistance, Current Cardiovascular Risk Reports, 2008, 2, 1, 72

    CrossRef

  95. 95
    Richard H. Moseley, Therapy for Nonalcoholic Fatty Liver Disease, Journal of Clinical Gastroenterology, 2008, 42, 4, 332

    CrossRef

  96. 96
    Mohammad R. Ebrahimkhani, Ahmed M. Elsharkawy, Derek A. Mann, Wound healing and local neuroendocrine regulation in the injured liver, Expert Reviews in Molecular Medicine, 2008, 10,

    CrossRef

  97. 97
    Didier M Lambert, Giulio G Muccioli, Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players, Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 6, 735

    CrossRef

  98. 98
    Brent A. Neuschwander-Tetri, Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma, Hepatology, 2007, 46, 1
    Direct Link:
  99. 99
    Matthias Banasch, Oliver Goetze, Wolfgang E. Schmidt, Juris J. Meier, Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis, Liver International, 2007, 27, 8
    Direct Link:
  100. 100
    Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, Peter Zahradka, Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae,
    Direct Link:
  101. 101
    Scott L. Friedman, Hepatic Fibrosis,
    Direct Link:
  102. 102
    Christopher P Day, Non-Alcoholic Fatty Liver Disease,
    Direct Link:
View Full Article (HTML) Get PDF (431K)